HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol. METHODS: A post hoc analysis of the recently completed Treating to New Targets (TNT) study assessed the predictive value of HDL cholesterol levels in 9770 patients. The primary outcome measure was the time to a first major cardiovascular event, defined as death from coronary heart disease, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. The predictive relationship between HDL cholesterol levels at the third month of treatment with statins and the time to the first major cardiovascular event was assessed in univariate and multivariate analyses and was also assessed for specific LDL cholesterol strata, including subjects with LDL cholesterol levels below 70 mg per deciliter (1.8 mmol per liter). RESULTS: The HDL cholesterol level in patients receiving statins was predictive of major cardiovascular events across the TNT study cohort, both when HDL cholesterol was considered as a continuous variable and when subjects were stratified according to quintiles of HDL cholesterol level. When the analysis was stratified according to LDL cholesterol level in patients receiving statins, the relationship between HDL cholesterol level and major cardiovascular events was of borderline significance (P=0.05). Even among study subjects with LDL cholesterol levels below 70 mg per deciliter, those in the highest quintile of HDL cholesterol level were at less risk for major cardiovascular events than those in the lowest quintile (P=0.03). CONCLUSIONS: In this post hoc analysis, HDL cholesterol levels were predictive of major cardiovascular events in patients treated with statins. This relationship was also observed among patients with LDL cholesterol levels below 70 mg per deciliter. (ClinicalTrials.gov number, NCT00327691 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies have shown that HDL cholesterol (HDL-C) levels under statin treatment remain an independent predictor of the risk of cardiovascular events in patients who have been treated with statins to lower LDL-C levels4”
From MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice (2012) · cites this paper as [4]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.151”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [151]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [292]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Self-citationDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- 10.1001/jama.251.3.351 · DOI · Paper page
Cited by
Items 401–500 of 1,001
Satoh, H., Ohira, T., Nagai, M., Hosoya, M., Sakai, A., Watanabe, T., Ohtsuru, A., Kawasaki, Y., Suzuki, H., Takahashi, A., et al. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.6030 · Cited by 36
An update on efflux and uptake transporters as determinants of statin response
Rocha, K. C. E., Pereira, B. M. V., & Rodrigues, A. C. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1482276 · Cited by 42
“Moreover, it might represent a source of residual cardiovascular risk in statintreated patients [124].”
BackgroundLipid efflux mechanisms, relation to disease and potential therapeutic aspects
Castaño, D., Rattanasopa, C., Monteiro-Cardoso, V. F., Corlianò, M., Liu, Y., Zhong, A., Rusu, M., Liehn, E. A., & Singaraja, R. R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.013 · Cited by 38
Roe, M. T., Ou, F., Alexander, K. P., Newby, L. K., Foody, J. M., Gibler, W. B., Boden, W. E., Ohman, E. M., Smith, S. C., & Peterson, E. D. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn364 · Cited by 37
Role of sphingosine 1-phosphate in anti-atherogenic actions of high-density lipoprotein
Sato, K., & Okajima, F. (2010) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v1.i11.327 · Cited by 42
Vazzana, N., Ganci, A., Cefalu, A. B., Lattanzio, S., Noto, D., Santoro, N., Saggini, R., Puccetti, L., Averna, M. R., & Davì, G. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000063 · Cited by 41
Amigó, N., Mallol, R., Heras, M., Martínez‐Hervás, S., Blanco‐Vaca, F., Escolá‐Gil, J. C., Plana, N., Yanes, Ó., Masana, L., & Correig, X. (2016) · Scientific Reports · doi:10.1038/srep19249 · Cited by 42
Sphingolipid Synthetic Pathways are Major Regulators of Lipid Homeostasis
Worgall, T. S. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0650-1_9 · Cited by 43
Chami, B., Barrie, N., Cai, X., Wang, X., Paul, M., Morton-Chandra, R., Sharland, A., Dennis, J., Freedman, S., & Witting, P. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160511101 · Cited by 36
Toms, T. E., Smith, J., Panoulas, V. F., Blackmore, H. L., Douglas, K., & Kitas, G. D. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.110683 · Cited by 43
Erectile Dysfunction: A Harbinger or Consequence: Does Its Detection Lead to a Window of Curability?
Miner, M. M. (2011) · Journal of Andrology · doi:10.2164/jandrol.110.011338 · Cited by 38
Wang, L., Hu, C., Liu, S., Ming, C., Gao, P., Wang, L., Pan, Z., & Xu, G. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00170 · Cited by 36
Xanthohumol, a hop-derived prenylated flavonoid, promotes macrophage reverse cholesterol transport
Hirata, H., Uto‐Kondo, H., Ogura, M., Ayaori, M., Shiotani, K., Ota, A., Tsuchiya, Y., & Ikewaki, K. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.04.011 · Cited by 38
Zhu, L., Luu, T. N., Emfinger, C. H., Parks, B. A., Shi, J., Trefts, E., Zeng, F., Kuklenyik, Z., Harris, R. C., Wasserman, D. H., et al. (2018) · Diabetes · doi:10.2337/db18-0474 · Cited by 40
Kawano, Y., Tamura, A., & Kadota, J. (2011) · Metabolism · doi:10.1016/j.metabol.2011.06.004 · Cited by 42
“Because it has been shown that elevated LDL-C/HDL-C is associated with increased cardiovascular events [8-11] and progression of coronary atherosclerosis [12], the increase in LDL-C/HDL-C in proportion to the severity of OSA may partly explain why patients with OSA, especially those with severe OSA, are at an increase…”
BackgroundInfluentialBalu, S., Simko, R. J., Quimbo, R. M., & Cziraky, M. J. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903297741 · Cited by 36
Hirata, H., Yimin, Segawa, S., Ozaki, M., Kobayashi, N., Shigyo, T., & Chiba, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049415 · Cited by 40
Low high-density lipoprotein cholesterol: current status and future strategies for management
Singh, V. N., Sharma, R., Kumar, A., & Deedwania, P. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5685 · Cited by 48
HMGA1 is a novel candidate gene for myocardial infarction susceptibility
Rosa, S. D., CHIEFARI, E. D., Salerno, N., Ventura, V., D’Ascoli, G. L., Arcidiacono, B., Ambrosio, G., Bilotta, F. L., Torella, D., FOTI, D. P., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.088 · Cited by 34
Effect of menopause on cardiovascular disease and its risk factors: a 9-year follow-up study
Tehrani, F. R., Behboudi‐Gandevani, S., Ghanbarian, A., & Azizi, F. (2013) · Climacteric · doi:10.3109/13697137.2013.828197 · Cited by 40
Translating Evidence of HDL and Plaque Regression
Bartolo, B. A. D., Psaltis, P. J., Bursill, C. A., & Nicholls, S. J. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.307026 · Cited by 39
Okala, S., Sise, E. A., Sosseh, F., Prentice, A. M., Woollett, L. A., & Moore, S. E. (2020) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-020-2834-1 · Cited by 49
Cardiovascular Effects of Sphingosine-1-Phosphate (S1P)
Levkau, B. (2013) · Handbook of experimental pharmacology · doi:10.1007/978-3-7091-1511-4_8 · Cited by 37
Tani, S., Nagao, K., Anazawa, T., Kawamata, H., Furuya, S., Takahashi, H., Iida, K., Matsumoto, M., Washio, T., Kumabe, N., et al. (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0705 · Cited by 36
Lozano, J. V., Pallarés‐Carratalá, V., Cea‐Calvo, L., Llisterri, J. L., Fernández, C., Martí-Canales, J. C., Aznar, J., Gil-Guillén, V. F., Redón, J., & on behalf of the investigators of the PReV-ICTUS Study (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x273372 · Cited by 36
The Safety of Niacin in the US Food and Drug Administration Adverse Event Reporting Database
Alsheikh-Ali, A. A. A., & Karas, R. H. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.027 · Cited by 35
Phytochemical Analysis and Hypolipidemic Properties of Jatropha tanjorensis Leaf Extract
Oyewole, O. I. (2011) · European Journal of Medicinal Plants · doi:10.9734/ejmp/2011/497 · Cited by 35
Jones, P. H., Bays, H. E., Davidson, M. H., Kelly, M. T., Buttler, S. M., Setze, C. M., Sleep, D. J., & Stolzenbach, J. C. (2008) · Clinical Drug Investigation · doi:10.2165/00044011-200828100-00003 · Cited by 37
Yang, Y., Zhang, J., Jia, L., Su, J.-N., Ma, M., & Lin, X. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1226108 · Cited by 40
“In addition, several studies have shown that low HDL-C levels in patients with AMI can predict MACEs (8, 30).”
BackgroundInfluentialNovel Therapies Focused on the High-Density Lipoprotein Particle
van Capelleveen, J. C., Brewer, H. B., Kastelein, J. J. P., & Hovingh, G. K. (2014) · Circulation Research · doi:10.1161/circresaha.114.301804 · Cited by 40
Self-citationTargeted next-generation sequencing to diagnose disorders of HDL cholesterol
Sadananda, S. N., Foo, J. N., Toh, M. T., Cermakova, L., Trigueros‐Motos, L., Chan, T., Liany, H., Collins, J. A., Gerami, S., Singaraja, R. R., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p058891 · Cited by 36
How to improve cardiovascular diseases prevention in Europe?
Reiner, Ž. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.06.006 · Cited by 41
Effects of Lifestyle Modification Programs on Cardiac Risk Factors
Razavi, M., Fournier, S., Shepard, D. S., Ritter, G. A., Strickler, G. K., & Stason, W. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114772 · Cited by 40
Stabilization of high-risk plaques
Takata, K., Imaizumi, S., Zhang, B., Miura, S., & Saku, K. (2016) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2015.10.03 · Cited by 42
Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?
Barter, P. J., & Rye, K. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.07.021 · Cited by 35
Self-citationZhang, B., Kawachi, E., Miura, S.-I., Uehara, Y., Matsunaga, A., Kuroki, M., & Saku, K. (2013) · Circulation Journal · doi:10.1253/circj.cj-12-1584 · Cited by 40
Cholesteryl ester transfer protein inhibitors: challenges and perspectives
Filippatos, T. D., Klouras, E., Barkas, F., & Elisaf, M. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1189327 · Cited by 36
Lipid phenotypes in patients with nonalcoholic fatty liver disease
Du, T., Sun, X., Yuan, G., Zhou, X., Lü, H., Lin, X., & Yu, X. (2016) · Metabolism · doi:10.1016/j.metabol.2016.06.006 · Cited by 34
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future
Kalaycı, A., Gibson, C. M., Ridker, P. M., Wright, S. D., Kingwell, B. A., Korjian, S., Chi, G., Lee, J., Tricoci, P., Kazmi, S. H. A., et al. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01025-7 · Cited by 38
Residual risks and evolving atherosclerotic plaques
Noothi, S. K., Ahmed, M. R., & Agrawal, D. K. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04689-0 · Cited by 48
Colhoun, H. M., Leiter, L. A., Müller-Wieland, D., Cariou, B., Ray, K. K., Tinahones, F. J., Domenger, C., Letierce, A., Israel, M., Samuel, R., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0991-1 · Cited by 33
Ng, D. S., Wong, N. C. W., & Hegele, R. A. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.238 · Cited by 38
Rudolf, J. W., & Lewandrowski, K. B. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2013.11.003 · Cited by 35
“Even in patients with an LDL less than 70 mg/dL, the therapeutic target for patients with established CHD, HDL remains an independent predictor of cardiovascular death.(10) This observation, along with the discovery of a series of novel markers of cardiovascular risk in the 10 years since the ATP-III’s publication, ar…”
Ogita, M., Miyauchi, K., Miyazaki, T., Naito, R., Konishi, H., Tsuboi, S., Dohi, T., Kasai, T., Yokoyama, T., Okazaki, S., et al. (2013) · Heart and Vessels · doi:10.1007/s00380-013-0330-5 · Cited by 36
Are Metabolic Factors Associated With Coronary Artery Stenosis on MDCT?
Mitsutake, R., Miura, S., Kawamura, A., & Saku, K. (2008) · Circulation Journal · doi:10.1253/circj.cj-08-0416 · Cited by 35
Succurro, E., Arturi, F., Grembiale, A., Iorio, F., Laino, I., Andreozzi, F., Sciacqua, A., Hribal, M. L., Perticone, F., & Sesti, G. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0113 · Cited by 32
Tong, X., Lv, P., Mathew, A. V., Liu, D., Niu, C., Wang, Y., Liang, J., Li, J., Fu, Z., Pan, B., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-82 · Cited by 34
Robertson, T., & Watts, E. L. (2015) · BMC Public Health · doi:10.1186/s12889-016-2796-4 · Cited by 46
HDL and Atherothrombotic Vascular Disease
Annema, W., von Eckardstein, A., & Kovanen, P. T. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_11 · Cited by 36
Relationship among low cholesterol levels, depressive symptoms, aggression, hostility, and cynicism
Sahebzamani, F. M., D’Aoust, R., Friedrich, D., Aiyer, A., Reís, S. E., & Kip, K. E. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.01.004 · Cited by 38
Shimizu, T., Miura, S.-I., Tanigawa, H., Kuwano, T., Zhang, B., Uehara, Y., & Saku, K. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303715 · Cited by 34
Kappelle, P. J. W. H., van Tol, A., Wolffenbuttel, B. H. R., & Dullaart, R. P. F. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00201.x · Cited by 33
Lu, Y., Zhou, S., Dreyer, R. P., Caulfield, M. P., Spatz, E. S., Geda, M. E., Lorenze, N. P., Herbert, P. N., D’Onofrio, G., Jackson, E. A., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.09.012 · Cited by 33
“This relationship remains significant even among patients with LDL-C b70 mg/dL.(28) However, whether increasing HDL-C level could translate into benefits of cardiovascular outcomes is still uncertain.”
Sim, W., Choi, S., Cho, B., Choi, S., Han, X., Cho, H.-D., Kim, S., Lee, B.-Y., Kang, I., Cho, J., et al. (2019) · Foods · doi:10.3390/foods8050170 · Cited by 32
“TC may decrease when LDL-cholesterol levels, often referred to as bad hormones, are suppressed [23].”
BackgroundImmunomodulatory and Metabolic Changes after Gnetin-C Supplementation in Humans
Nakagami, Y., Suzuki, S., Espinoza, J. L., Quang, L. V., Enomoto, M., Takasugi, S., Nakamura, A., Nakayama, T., Tani, H., Hanamura, I., et al. (2019) · Nutrients · doi:10.3390/nu11061403 · Cited by 32
Sergi, D., Zauli, E., Tisato, V., Secchiero, P., Zauli, G., & Cervellati, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054403 · Cited by 34
Jones, P. H. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.074 · Cited by 33
Toyama, K., Sugiyama, S., Oka, H., Iwasaki, Y., Sumida, H., Tanaka, T., Tayama, S., Jinnouchi, H., Matsui, K., & Ogawa, H. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.02.050 · Cited by 34
Ghazzal, Z. B., Dhawan, S. S., Sheikh, A., Douglas, J. S., Veledar, E., Mavromatis, K., Pohlel, F. K., & Vaccarino, V. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.11.053 · Cited by 33
A Very High Prevalence of Low HDL Cholesterol in Spanish Patients With Acute Coronary Syndromes
Pintó, X., Millán, J., Muñoz, A., Corbella, E., Hernández‐Mijares, A., Zuñiga, M., Mangas, A., & Pedro‐Botet, J. (2010) · Clinical Cardiology · doi:10.1002/clc.20774 · Cited by 36
Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects
Mijares, A. H., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Mantilla, T., Pedro‐Botet, J., Pintó, X., & Millán, J. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.02.002 · Cited by 37
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Tunnicliffe, D. J., Palmer, S. C., Cashmore, B. A., Saglimbene, V. M., Krishnasamy, R., Lambert, K., Johnson, D. W., Craig, J. C., & Strippoli, G. F. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub3 · Cited by 53
Association of dyslipidaemia with cholilithiasis and effect of cholecystectomy on the same
Malik, A. A., Wani, M. L., Tak, S. I., Irshad, I., & Ul-Hassan, N. (2011) · International Journal of Surgery · doi:10.1016/j.ijsu.2011.08.003 · Cited by 43
HDL-C: clinical equipoise and vascular endothelial function
Campbell, S., & Genest, J. J. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.13.17 · Cited by 36
Examination of the FDA Warning for Statins and Cognitive Dysfunction
Sahebzamani, F. M. (2014) · Journal of Pharmacovigilance · doi:10.4172/2329-6887.1000141 · Cited by 33
Ascaso, J. F., Millán, J., Hernández‐Mijares, A., Blasco, M., Brea, Á., Rodríguez, Á. D., Mantilla, T., Pedro‐Botet, J., & Pintó, X. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.11.001 · Cited by 31
Khorshidi, M., Zarezadeh, M., Moghaddam, O. M., Emami, M. R., Kord‐Varkaneh, H., Mousavi, S. M., Alizadeh, S., Heshmati, J., Olang, B., & Aryaeian, N. (2020) · Phytotherapy Research · doi:10.1002/ptr.6716 · Cited by 34
“Former studies have shown that high LDL and TG and low HDL levels are determinant factors for the progress of atherosclerosis and cardiovascular complications (Barter et al., 2007; Gordon, Kannel, Castelli, & Dawber, 1981).”
BackgroundLee, S., Lee, M.-S., Chang, E., Lee, Y., Lee, J., Kim, J., Kim, C., Kim, I.-H., & Kim, Y. (2020) · Nutrients · doi:10.3390/nu12051499 · Cited by 35
“Given a negative correlation between HDL-C levels and the risk of CVD, HDL-C has been demonstrated as a strong predictor of CVD [4,5].”
BackgroundInfluentialZheng, K. H., Kaiser, Y., van Olden, C. C., Santos, R. D., Dasseux, J., Genest, J. J., Gaudet, D., Westerink, J., Keyserling, C., Verberne, H. J., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.08.004 · Cited by 36
Söderlund, S., Watanabe, H., Ehnholm, C., Jauhiainen, M., & Taskinen, M. (2010) · Metabolism · doi:10.1016/j.metabol.2010.01.015 · Cited by 33
“A low level of high-density lipoprotein cholesterol (HDLC) is an independent, powerful risk factor for cardiovascular disease [1], even in patients with effective statin therapy and a very low level of low-density lipoprotein cholesterol (LDL-C) [2].”
BackgroundSapbamrer, R., Visavarungroj, N., & Suttajit, M. (2013) · PubMed · doi:10.6133/apjcn.2013.22.2.17 · Cited by 33
Li, X.-Z., Ding, Y., Wu, H., Bian, Z., Xu, J.-D., Gu, C., Chen, X., & Yang, D. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000486166 · Cited by 31
Non-Coding RNAs and Lipid Metabolism
Smolle, E., & Haybaeck, J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150813494 · Cited by 32
Farnier, M., Steinmetz, A., Retterstøl, K., & Császár, A. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.02.006 · Cited by 30
Ong, K. L., Wu, B. J., Cheung, B. M. Y., Barter, P. J., & Rye, K. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.07.094 · Cited by 30
Self-citationCurrent guidelines for high-density lipoprotein cholesterol in therapy and future directions
Michos, E. D., Subedi, B. H., Joshi, P. H., Jones, S. R., Martin, S. S., & Blaha, M. J. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s45648 · Cited by 37
Consenso de expertos sobre propuestas para la mejora del manejo de la dislipemia aterogénica
Núñez-Cortés, J. M., Pedro‐Botet, J., Brea-Hernando, Á., Rodríguez, Á. D., González‐Santos, P., Hernández‐Mijares, A., Mantilla, T., Pintó, X., & Simó, R. (2013) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.06.014 · Cited by 34
Landmesser, U., von Eckardstein, A., Kastelein, J. J. P., Deanfield, J. E., & Lüscher, T. F. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs182 · Cited by 30
Self-citationPadala, S. K., Sidhu, M. S., & Boden, W. E. (2016) · Springer eBooks · doi:10.1007/978-3-642-37393-0_70-2 · Cited by 30
“HDL Cholesterol (HDL-C) Observational data in patients with established CAD have shown that low levels of HDL-C is associated with an incremental risk for adverse coronary events, despite low levels of LDL cholesterol (Barter et al. 2007; Acharjee et al. 2013).”
BackgroundBerryman, C. E., Fleming, J. A., & Kris‐Etherton, P. M. (2017) · Journal of Nutrition · doi:10.3945/jn.116.245126 · Cited by 32
Effects of Helicobacter pylori eradication on serum lipid levels
Adachi, K., Mishiro, T., Toda, T., Kano, N., Fujihara, H., Mishima, Y., Konishi, A., Mochida, M., Takahashi, K., & Kinoshita, Y. (2018) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.17-88 · Cited by 35
Prevalence and Determinants of Dyslipidemia: Data from a Saudi University Clinic
Al-Hassan, Y. T., Fabella, E. L., Estrella, E. D., & Aatif, M. (2018) · The Open Public Health Journal · doi:10.2174/1874944501811010416 · Cited by 30
Sasaki, M., Delawary, M., Sakurai, H., Kobayashi, H., Nakao, N., Tsuru, H., Fukushima, Y., Honzumi, S., Moriyama, S., Wada, N., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314516 · Cited by 29
Pharmacological interventions for heart failure in people with chronic kidney disease
Lunney, M., Ruospo, M., Natale, P., Quinn, R. R., Ronksley, P. E., Konstantinidis, I., Palmer, S. C., Tonelli, M. A., Strippoli, G. F., & Ravani, P. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466.pub2 · Cited by 42
Kim, S., Park, K., Hong, S.-J., Cho, Y., Sung, J.-D., Moon, G.-W., Yoon, M.-H., Lee, M.-Y., Hyon, M., Kim, D. W., et al. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.10.004 · Cited by 34
Holy, E. W., Besler, C., Reiner, M. F., Camici, G. G., Manz, J., Beer, J. H., Lüscher, T. F., Landmesser, U., & Tanner, F. C. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-09-0775 · Cited by 32
Warncke, K., Liptay, S., Fröhlich-Reiterer, E. E., Scheuing, N., Schebek, M., Wolf, J., Rohrer, T. R., Meißner, T., & Holl, R. W. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12261 · Cited by 32
Yadav, R., Liu, Y., Kwok, S., Hama, S., France, M. W., Eatough, R., Pemberton, P., Schofield, J. D., Siahmansur, T. J., Malik, R. A., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001508 · Cited by 29
Anacetrapib and Dalcetrapib: Two Novel Cholesteryl Ester Transfer Protein Inhibitors
Miyares, M. A. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p446 · Cited by 30
Protective Effects of HDL Against Ischemia/Reperfusion Injury
Gomaraschi, M., Calabresi, L., & Franceschini, G. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00002 · Cited by 32
Phytochemical Composition: Antioxidant Potential and Biological Activities of Corn
Nawaz, H., Muzaffar, S., Aslam, M., & Ahmad, S. (2018) · InTech eBooks · doi:10.5772/intechopen.79648 · Cited by 29
Sharif‐Askari, F. S., Sharif‐Askari, N. S., Halwani, R., Abusnana, S., Hamoudi, R., & Sulaiman, N. D. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s245742 · Cited by 35
Genoux, A., Ruidavets, J., Ferrières, J., Combes, G., Lichtenstein, L., Pons, V., Laffargue, M., Taraszkiewicz, D., Carrié, D., Elbaz, M., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.p036335 · Cited by 31
von Eckardstein, A. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.6 · Cited by 32
Tavoosi, Z., Moradi‐Sardareh, H., Saidijam, M., Yadegarazari, R., Borzuei, S., Soltanian, A. R., & Goodarzi, M. T. (2015) · Cholesterol · doi:10.1155/2015/682904 · Cited by 28
Morrow, D. A., & Boden, W. E. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00057-3 · Cited by 32
Emerging lipid-lowering drugs: squalene synthase inhibitors
Elsayed, R. K., & Evans, J. D. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.2.309 · Cited by 30
HDL metabolism in context: looking on the bright side
Watts, G. F., Barrett, P. H. R., & Chan, D. C. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328306596d · Cited by 34
Zhu, H., Ye, G., Xie, Y., Zhu, K., Zhu, F., & Chen, Q. (2022) · Clinical Oral Investigations · doi:10.1007/s00784-022-04439-4 · Cited by 28
HDL abnormalities in type 2 diabetes: Clinical implications
Martagón, A. J., Zubirán, R., González-Arellanes, R., Praget-Bracamontes, S., Rivera-Alcántara, J. A., & Aguilar-Salinas, C. A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117213 · Cited by 34
Metadata
- Authors
- Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C.
- Affiliations
- The Heart Research Institute (AU)
- Cornell University (US)
- SUNY Downstate Health Sciences University (US)
- Pfizer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Alabama (US)
- Institut Pasteur de Lille (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-09-27
- Volume
- 357
- Issue
- 13
- Pages
- 1301-1310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158057499
- Cited by
- 1,610
- References
- 24
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 34 · 2023: 48 · 2022: 36 · 2021: 51 · 2020: 79 · 2019: 72 · 2018: 59 · 2017: 75 · 2016: 90 · 2015: 106 · 2014: 128 · 2013: 126 · 2012: 130
- FWCI
- 113.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HDL cholesterol, LDL cholesterol, very low LDL cholesterol, major cardiovascular events, statin therapy, cardiovascular risk prediction, coronary artery disease, myocardial infarction, stroke, low HDL cholesterol
- MeSH terms
- Atorvastatin, Adult, Aged, Anticholesteremic Agents, Apolipoproteins, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Risk, Multivariate Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.